Related Experiment Videos
The first potent and selective inhibitors of the glycine transporter type 2
W L Caulfield1, I T Collie, R S Dickins
1Lead Discovery Unit, Organon Laboratories Ltd., Newhouse ML1 5SH, Scotland, UK.
Journal of Medicinal Chemistry
|August 10, 2001
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Quality-of-Life Analysis of a Phase II Randomised Controlled Trial Comparing Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy in Locally Advanced Rectal Cancer.
Clinical oncology (Royal College of Radiologists (Great Britain))·2024
A randomized trial testing the efficacy of modifications to the nutrition facts table on comprehension and use of nutrition information by adolescents and young adults in Canada.
Health promotion and chronic disease prevention in Canada : research, policy and practice·2015
How better is random blinded re-checking results in revised national TB Control Programme, India?
Indian journal of medical microbiology·2015
Structural and Mechanistic Studies of ADEPs Yield Potent Antibacterials and a Drug Formulation Strategy for Tuberculosis.
Journal of medicinal chemistry·2026
A 177Lu-Labeled Circular Bivalent Aptamer for PTK7-Targeting Radionuclide Therapy in Ovarian Cancer and Orthotopic Hepatoblastoma.
Journal of medicinal chemistry·2026
From Fragment Hit to Clinical Candidate: Discovery of Dual H1R/H4R Ligands with Superior Efficacy in Allergic Conjunctivitis.
Journal of medicinal chemistry·2026
Potent Anticancer Tethered Organorhodium(III) Complexes Target the Mitochondria.
Journal of medicinal chemistry·2026
Discovery of a Covalent NLRP3 LRR-Domain Probe: Reversing Renal Fibrosis via Immunometabolic Reprogramming in Organoid and Murine Models.
Journal of medicinal chemistry·2026
Lead Optimization of Multimutant KRAS Switch-II Pocket Macrocyclic Inhibitors via Isosteric Replacement to Improve ADME and Oral Exposure.
Journal of medicinal chemistry·2026
KAN-GIN: Adaptive Nonlinear Molecular Representation Learning for Drug-Target Affinity Prediction.
Pharmaceuticals (Basel, Switzerland)·2026
Design, Synthesis, and Biological Evaluation of Novel ML-167 Analogues as Therapeutic Candidates Against Sarcopenia-Induced Muscle Wasting.
Pharmaceuticals (Basel, Switzerland)·2026
Integrated Machine Learning and Molecular Simulation-Guided Discovery of Novel Small-Molecule PD-L1 Inhibitors.
Pharmaceuticals (Basel, Switzerland)·2026
Design, Synthesis, and Integrated In Silico and In Vitro Evaluation of Chloro-Substituted Salicylaldehyde Benzoylhydrazones as Anticancer Agents.
Pharmaceuticals (Basel, Switzerland)·2026
Design, Synthesis, and Cytotoxic Evaluation of N-Phenyl-3-(Thiophen-2-Yl)acrylamide Derivatives.
Molecules (Basel, Switzerland)·2026
Integrating Pharmacodynamic Data to Prioritise Candidate Migraine Genes and Pathways Using a Novel Bioinformatics Workflow.
Journal of clinical medicine·2026